Major adverse events, pretransplant assessment and outcome prediction

Journal of Gastroenterology and Hepatology (Australia)

Volumn 24, Issue 11, 2009, Pages 1716-1724

  Huang, Hui Chun ^a,b   Lee, Fa Yauh ^a,b   Huo, Teh Ia ^a,b  

^a TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

^b NATIONAL YANG MING UNIVERSITY   (Taiwan)

Author keywords

Liver cirrhosis; Liver transplantation; Model for end stage liver disease; Model for end stage liver disease sodium; Portal hypertension; Sodium

Indexed keywords

SODIUM;

ASIAN; CADAVER DONOR; CULTURAL FACTOR; ESOPHAGUS VARICES BLEEDING; FEASIBILITY STUDY; HEPATIC ENCEPHALOPATHY; HEPATOPULMONARY SYNDROME; HEPATORENAL SYNDROME; HOSPITAL ADMISSION; HUMAN; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER FAILURE; LIVER TRANSPLANTATION; OUTCOME ASSESSMENT; PATHOPHYSIOLOGY; PORTAL HYPERTENSION; PORTOPULMONARY HYPERTENSION; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; PROGNOSIS; RECIPIENT; RELIGION; REVIEW; SCORING SYSTEM; SODIUM BLOOD LEVEL;

EID: 70449393850     PISSN: 08159319     EISSN: 14401746     Source Type: Journal    
DOI: 10.1111/j.1440-1746.2009.06025.x     Document Type: Review

References (94)

1. Hernandez-Guerra M, Garcia-Pagan JC, Bosch J. Increased hepatic resistance: a new target in the pharmacologic therapy of portal hypertension. J. Clin. Gastroenterol. 2005 39 : S131 137.
2. Wiest R, Groszmann RJ. The paradox of nitric oxide in cirrhosis and portal hypertension: too much, not enough. Hepatology 2002 35 : 478 491.
3. Sandhu BS, Sanyal AJ. Management of ascites in cirrhosis. Clin. Liver Dis. 2005 9 : 715 732.
4. Arroyo V, Colmenero J. Ascites and hepatorenal syndrome in cirrhosis: pathophysiological basis of therapy and current management. J. Hepatol. 2003 38 : S69 89.
5. Fallon MB. Portopulmonary hypertension: new clinical insights and more questions on pathogenesis. Hepatology 2003 37 : 253 255.
6. D'Amico G, Pagliaro L, Bosch J. The treatment of portal hypertension: a meta-analytic review. Hepatology 1995 22 : 332 354.
7. McCormick PA, O'Keefe C. Improving prognosis following a first variceal hemorrhage over four decades. Gut 2001 49 : 682 685.
8. Graham DY, Smith JL. The course of patients after variceal hemorrhage. Gastroenterology 1981 80 : 800 809.
9. Khuroo MS, Khuroo NS, Farahat KL, Khuroo YS, Sofi AA, Dahab ST. Meta-analysis: endoscopic variceal ligation for primary prophylaxis of oesophageal variceal bleeding. Aliment. Pharmacol. Ther. 2005 21 : 347 361.
10. Norberto L, Polese L, Cillo U et al. A randomized study comparing ligation with propranolol for primary prophylaxis of variceal bleeding in candidates for liver transplantation. Liver Transpl. 2007 13 : 1272 1278.
11. O'Carroll RE, Couston M, Cossar J, Masterton G, Hayes PC. Psychological outcome and quality of life following liver transplantation: a prospective, national, single-center study. Liver Transpl. 2003 9 : 712 720.
12. Mechtcheriakov S, Graziadei IW, Mattedi M et al. Incomplete improvement of visuo-motor deficits in patients with minimal hepatic encephalopathy after liver transplantation. Liver Transpl. 2004 10 : 77 83.
13. D'Amico G, Morabito A, Pagliaro L, Marubini E. Survival and prognostic indicators in compensated and decompensated cirrhosis. Dig. Dis. Sci. 1986 31 : 468 475.
14. Kim SU, Han KH, Nam CM et al. Natural history of hepatitis B virus-related cirrhotic patients hospitalized to control ascites. J. Gastroenterol. Hepatol. 2008 23 : 1722 1727.
15. Gines A, Escorsell A, Gines P et al. Incidence, predictive factors, and prognosis of the hepatorenal syndrome in cirrhosis with ascites. Gastroenterology 1993 105 : 229 236.
16. Gonwa TA, Morris CA, Goldstein RM, Husberg BS, Klintmalm GB. Long-term survival and renal function following liver transplantation in patients with and without hepatorenal syndrome: experience in 300 patients. Transplantation 1991 51 : 428 430.
17. Mathews RI Jr., McGuire BM, Estrada CA. Outpatient management of cirrhosis: a narrative review. South Med. J. 2006 99 : 600 606.
18. Krowka MJ, Porayko MK, Plevak DJ et al. Hepatopulmonary syndrome with progressive hypoxemia as an indication for liver transplantation: case reports and literature review. Mayo Clin. Proc. 1997 72 : 44 53.
19. Hadengue A, Benahyoun M, Lebrec D, Benhamou JP. Pulmonary hypertension complicating portal hypertension: prevalence and relation to splanchnic hemodynamics. Gastroenterology 1991 100 : 520 528.
20. Ramsay MA, Simpson BR, Nguyen AT, Ramsay KJ, East C, Klintmalm GB. Severe pulmonary hypertension in liver transplant candidates. Liver Transpl. Surg. 1997 3 : 494 500.
21. Herve P, Le Pavec J, Sztrymf B, Decante B, Savale L, Sitbon O. Pulmonary vascular abnormalities in cirrhosis. Best. Pract. Res. Clin. Gastroenterol. 2007 21 : 141 159.
22. Plotkin JS, Kuo PC, Rubin LJ et al. Successful use of chronic epoprostenol as a bridge to LT in severe portopulmonary hypertension. Transplantation 1998 65 : 457 459.
23. Starzl TE, Todo S, Gordon RD et al. Liver transplantation in older patients. N. Engl. J. Med. 1987 316 : 484 485.
24. Zetterman RK, Belle SH, Hoofnagle JH et al. Age and liver transplantation: a report of the liver transplantation database. Transplantation 1998 66 : 500 506.
25. Herrero JI, Lucena JF, Quiroga J et al. Liver transplant recipients older than 60 years have lower survival and higher incidence of malignancy. Am. J. Transplant. 2003 3 : 1407 1412.
26. Pungpapong S, Manzarbeitia C, Ortiz J et al. Cigarette smoking is associated with an increased incidence of vascular complications after liver transplantation. Liver Transpl. 2002 8 : 582 587.
27. Pfitzmann R, Schwenzer J, Rayes N, Seehofer D, Neuhaus R, Nussler NC. Long-term survival and predictors of relapse after orthotopic liver transplantation for alcoholic liver disease. Liver Transpl. 2007 13 : 197 205.
28. Mathurin P, Lucey MR. A patient with alcoholic liver failure referred for liver transplantation. Liver Transpl. 2007 13 : S83 S86.
29. Gish RG, Lee A, Brooks L, Leung J, Lau JY, Moore DH II. Long-term follow-up of patients diagnosed with alcohol dependence or alcohol abuse who were evaluated for liver transplantation. Liver Transpl. 2001 7 : 581 587.
30. Lim JK, Keeffe EB. Liver transplantation for alcoholic liver disease: current concepts and length of sobriety. Liver Transpl. 2004 10 : S31 S38.
31. Bear DM, Paulson RA, Williams RH. Cut-off and toxicity levels for drugs-of-abuse testing. Med. Lab. Obs, 2004 36 : 10 1.
32. Ranneya DN, Ackera WB, Al-Holoua SN et al. Marijuana use in potential liver transplant candidates. Am. J. Transplant. 2009 9 : 280 285.
33. Briet F, Aqel BA, Jeejeebhoy KN, Scolapio JS. A low pretransplant peripheral blood mononuclear cell complex I activity predicts metabolic disturbances and inability to regain fat free mass in cirrhotic patients undergoing liver transplantation. Nutr. Res. 2009 29 : 26 34.
34. Sokhi RP, Anantharaju A, Kondaveeti R, Creech SD, Islam KK, Van Thiel DH. Bone mineral density among cirrhotic patients awaiting liver transplantation. Liver Transpl. 2004 10 : 648 653.
35. Trautwein C, Possienke M, Schlitt HJ et al. Bone density and metabolism in patients with viral hepatitis and cholestatic liver diseases before and after liver transplantation. Am. J. Gastroenterol. 2000 95 : 2343 2351.
36. Nair S, Verma S, Thuluvath PJ. Obesity and its effect on survival in patients undergoing orthotopic liver transplantation in the United States. Hepatology 2002 35 : 105 109. (Pubitemid 34032549)
37. Plotkin JS, Scott VL, Pinna A, Dobsch BP, De Wolf AM, Kang Y. Morbidity and mortality in patients with coronary artery disease undergoing orthotopic liver transplantation. Liver Transpl. Surg. 1996 2 : 426 430.
38. Williams K, Lewis JF, Davis G, Geiser EA. Dobutamine stress echocardiography in patients undergoing liver transplantation evaluation. Transplantation 2000 69 : 2354 2356.
39. Arguedas MR, Abrams GA, Krowka MJ, Fallon MB. Prospective evaluation of outcomes and predictors of mortality in patients with hepatopulmonary syndrome undergoing liver transplantation. Hepatology 2003 37 : 192 197.
40. Mazzaferro V, Regalia E, Doci R et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N. Engl. J. Med. 1996 334 : 693 699.
41. Yao FY, Xiao L, Bass NM, Kerlan R, Ascher NL, Roberts JP. LT for hepatocellular carcinoma: validation of the UCSF-expanded criteria based on preoperative imaging. Am. J. Transplant. 2007 7 : 2587 2596.
42. Hwang S, Lee SG, Joh JW, Suh KS, Kim DG. Liver transplantation for adult patients with hepatocellular carcinoma in Korea: comparison between cadaveric donor and living donor liver transplantation. Liver Transpl. 2005 11 : 1265 1272.
43. Todo S, Furukawa H. Living donor liver transplantation for adult patients with heptocellular carcinoma. Ann. Surg. 2004 240 : 451 459.
44. Soejima Y, Taketomi A, Yoshizumi T et al. Extended indication for living donor liver transplantation in patients with hepatocellular carcinoma. Transplantation 2007 83 : 893 899.
45. Moray G, Karakayali F, Yilmaz U, Ozcay F, Bilezikci B, Haberal M. Expanded criteria for hepatocellular carcinoma and liver transplantation. Transplant. Proc. 2007 39 : 1171 1174.
46. Toso C, Trotter J, Wei A et al. Total tumor volume predicts risk of recurrence following liver transplantation in patients with hepatocellular carcinoma. Liver Transpl. 2008 14 : 1107 1115.
47. Toso C, Asthana S, Bigam DL, Shapiro AM, Kneteman NM. Reassessing selection criteria prior to liver transplantation for hepatocellular carcinoma utilizing the Scientific Registry of Transplant Recipients database. Hepatology 2009 49 : 832 838.
48. Keeffe EB. Patient selection and listing policies for liver transplantation. J. Gastroenterol. Hepatol. 1999 14 (Suppl S42 47.
49. Fernandes H, Koneru B, Fernandes N et al. Investigation of promoter polymorphisms in the tumor necrosis factor-α and interleukin-10 genes in liver transplant patients. Transplantation 2002 73 : 1886 1891.
50. Jonsson JR, Hong C, Purdie DM et al. Role of cytokine gene polymorphisms in acute rejection and renal impairment after liver transplantation. Liver Transpl. 2001 7 : 255 263.
51. Xie HY, Wang WL, Yao MY et al. Polymorphisms in cytokine genes and their association with acute rejection and recurrence of hepatitis B in Chinese liver transplant recipients. Arch. Med. Res. 2008 39 : 420 428.
52. Yerdel MA, Gunson B, Mirza D et al. Portal vein thrombosis in adults undergoing liver transplantation: risk factors, screening, management, and outcome. Transplantation 2000 69 : 1873 1881.
53. de Villa VH, Lo CM, Chen CL. Ethics and rationale of living-donor liver transplantation in Asia. Transplantation 2003 75 : S2 S5.
54. Feng S, Goodrich NP, Bragg-Greshamb JL et al. Characteristics associated with liver graft failure: The concept of a donor risk index. Am. J. Transplant. 2006 6 : 783 790.
55. Kiuchi T, Kasahara M, Uryuhara K et al. Impact of graft size mismatching on graft prognosis in Lliver transplantation from living donors. Transplantation 1999 67 : 321 327.
56. Sugawara Y, Makuuchi M, Takayama T, Imamura H, Kaneko J. Right lateral sector graft in adult living-related liver transplantation. Transplantation 2002 73 : 111 114.
57. Tsang LL, Chen CL, Huang TL et al. Preoperative imaging evaluation of potential living liver donors: reasons for exclusion from donation in adult living donor liver transplantation. Transplant. Proc. 2008 40 : 2460 2462.
58. Vauthey JN, Abdalla EK, Doherty DA et al. Body surface area and body weight predict total liver volume in Western adults. Liver Transpl. 2002 8 : 233 240.
59. Yu HC, You H, Lee H, Jin ZW, Moon JI, Cho BH. Estimation of standard liver volume for liver transplantation in the Korean population. Liver Transpl. 2004 10 : 779 783.
60. Yuan D, Lu T, Wei YG et al. Estimation of standard liver volume for liver transplantation in the Chinese population. Transplant. Proc. 2008 40 : 3536 3540.
61. Hidden M, Christofferson P, Juhl E, Dalgaard JB. Liver histology in a 'normal' population - examination of 503 consecutive fatal traffic casualties. Scand. J. Gastroenterol. 1997 12 : 593 597.
62. Imber CJ, St. Peter SD, Handa A, Friend PJ. Hepatic steatosis and its relationship to transplantation. Liver Transpl. 2002 8 : 415 423.
63. Fukumori T, Ohkohchi N, Tsukamoto S, Satomi S. The mechanism of injury in a steatotic liver graft during cold preservation. Transplantation 1999 67 : 195 200.
64. Koneru B, Dikdan G. Hepatic steatosis and liver transplantation current clinical and experimental perspectives. Transplantation 2002 73 : 325 330.
65. Ghobrial RM, Saab S, Lassman C et al. Donor and recipient outcomes in right lobe adult living donor liver transplantation. Liver Transpl. 2002 8 : 901 909.
66. Nagai S, Fujimoto Y, Kamei H, Nakamura T, Kiuchi T. Mild hepatic macrovesicular steatosis may be a risk factor for hyperbilirubinaemia in living liver donors following right hepatectomy. Br. J. Surg. 2009 96 : 437 444.
67. Wu TJ, Lee CF, Chou HS, Yu MC, Lee WC. Suspect the donor with potential infection in the adult deceased donor liver transplantation. Transplant. Proc. 2008 40 : 2486 2488.
68. Hampel H, Bynum GD, Zamora E et al. Risk factors for the development of renal dysfunction in hospitalized patients with cirrhosis. Am. J. Gastroenterol. 2001 96 : 2206 2210.
69. De Franchis R, Salerno F. Pathogenesis of ascites and predictors of resistance to therapy. J. Gastroenterol. Hepatol. 2002 17 (Suppl. 3 S242 47.
70. Brown RS Jr., Lake JR. The survival impact of liver transplantation in the MELD era, and the future for organ allocation and distribution. Am. J. Transplant. 2005 5 : 203 204.
71. Fink MA, Angus PW, Gow PJ et al. Liver transplant recipient selection: MELD vs. clinical judgment. Liver Transpl. 2005 11 : 621 626.
72. Wiesner R, Edwards E, Freeman R et al. Model for end-stage liver disease (MELD) and allocation of donor livers. Gastroenterology 2003 124 : 91 6.
73. Salerno F, Merli M, Cazzaniga M et al. MELD score is better than Child-Pugh score in predicting 3-month survival of patients undergoing transjugular intrahepatic portosystemic shunt. J. Hepatol. 2002 36 : 494 500.
74. Huo TI, Wu JC, Lin HC et al. Evaluation of the increase in model for end-stage liver disease (delta MELD) score over time as a prognostic predictor in patients with advanced cirrhosis: risk factor analysis and comparison with initial MELD and Child-Turcotte-Pugh score. J. Hepatol. 2005 42 : 826 832.
75. Lladó L, Figueras J, Memba R et al. Is MELD really the definitive score for liver allocation? Liver Transpl. 2002 8 : 795 798.
76. Mishra P, Desai N, Alexander J et al. Applicability of MELD as a short-term prognostic indicator in patients with chronic liver disease: an Indian experience. J. Gastroenterol. Hepatol. 2007 22 : 1232 1235.
77. Chan HL, Chim AM, Lau JT et al. Evaluation of model for end-stage liver disease for prediction of mortality in decompensated chronic hepatitis B. Am. J. Gastroenterol. 2006 101 : 1516 1523.
78. Huo TI, Lin HC, Wu JC et al. Proposal of a modified Child-Turcotte-Pugh scoring system and comparison with the model for end-stage liver disease for outcome prediction in patients with cirrhosis. Liver Transpl. 2006 12 : 65 71.
79. Wang YW, Huo TI, Yang YY et al. Correlation and comparison of the model for end-stage liver disease, portal pressure, and serum sodium for outcome prediction in patients with liver cirrhosis. J. Clin. Gastroenterol. 2007 41 : 706 712.
80. Befeler AS, Palmer DE, Hoffman M et al. The safety of intra-abdominal surgery in patients with cirrhosis: model for end-stage liver disease score is superior to Child-Turcotte-Pugh classification in predicting outcome. Arch. Surg. 2005 140 : 650 654.
81. Huo TI, Lin HC, Hsia CY et al. The model for end-stage liver disease based cancer staging systems are better prognostic models for hepatocellular carcinoma: a prospective sequential survey. Am. J. Gastroenterol. 2007 102 : 1920 1930.
82. Limquiaco JL, Wong GL, Wong VW et al. Evaluation of model for end stage liver disease (MELD)-based systems as prognostic index for hepatocellular carcinoma. J. Gastroenterol. Hepatol. 2009 24 : 63 9.
83. Kamath PS, Wiesner RH, Malinchoc M et al. A model to predict survival in patients with end stage liver disease. Hepatology 2001 33 : 464 470.
84. Huo TI, Lin HC, Lee FY et al. Occurrence of cirrhosis-related complications is a time-dependent prognostic predictor independent of baseline model for end-stage liver disease score. Liver Int. 2006 26 : 55 61.
85. Stewart CA, Malinchoc M, Kim WR et al. Hepatic encephalopathy as a predictor of survival in patients with end-stage liver disease. Liver Transpl. 2007 13 : 1366 1371.
86. Biggins SW, Rodriguez HJ, Bacchetti P et al. Serum sodium predicts mortality in patients listed for liver transplantation. Hepatology 2004 41 : 32 9.
87. Mathur S, Gane EJ, McCall JL et al. Serum sodium and hydration status predict transplant-free survival independent of MELD score in patients with cirrhosis. J. Gastroenterol. Hepatol. 2008 23 : 239 243.
88. Heuman DM, Abou-Assi SG, Habib A et al. Persistent ascites and low serum sodium identify patients with cirrhosis and low MELD scores who are at high risk for early death. Hepatology 2004 40 : 802 810.
89. Biggins SW, Kim WR, Terrault NA et al. Evidence-based incorporation of serum sodium concentration into MELD. Gastroenterology 2006 130 : 1652 1660.
90. Kim WR, Biggins SW, Kremers WK et al. Hyponatremia and mortality among patients on the liver-transplant waiting list. N. Engl. J. Med. 2008 359 : 1018 1026.
91. Huo TI, Wang YW, Yang YY et al. Model for end-stage liver disease score to serum sodium ratio index as a prognostic predictor and its correlation with portal pressure in patients with liver cirrhosis. Liver Int. 2007 27 : 498 506.
92. Luca A, Angermayr B, Bertolini G et al. An integrated MELD model including serum sodium and age improves the prediction of early mortality in patients with cirrhosis. Liver Transpl. 2007 13 : 1174 1180.
93. Huo TI, Lin HC, Huo SC et al. Comparison of four model for end-stage liver disease-based prognostic systems for cirrhosis. Liver Transpl. 2008 14 : 837 844.
94. Wong VW, Chim AM, Wong GL et al. Performance of the new MELD-Na score in predicting 3-month and 1-year mortality in Chinese patients with chronic hepatitis B. Liver Transpl. 2007 13 : 1228 1235.